title: Direct evidence for systemic fibrinogenolysis in a patient with metastatic prostatic cancer.
abstract: Although the possible occurrence of systemic fibrinogenolysis has been suggested in patients with metastasising prostatic cancer (MPC), direct evidence is lacking. We report on a patient with MPC whose laboratory data were consistent with hyperfibrinolysis: marked decrease of alpha 2-antiplasmin (AP) level (less than 50% of normal), increase of plasmin-alpha 2-antiplasmin complex, D-fragment of fibrin and fibrinogen degradation products [FDP(D)] and cross-linked fibrin degradation products (XDP). The patient neither showed laboratory nor clinical evidence for consumption coagulopathy except for a slight increase in thrombin-antithrombin III complex level. Immunoblotting of the patient's serum using an anti-fibrinogen antibody revealed the presence of a 250 kDa protein in addition to DD fragments. Following reduction of this protein by 2-mercaptoethanol after extraction from SDS-PAGE gel, gamma-chain of fibrinogen (47 kDa) was found by immunoblotting using a monoclonal antibody recognising a 86-302 residue of the gamma-remnant of fibrinogen. Moreover, the 250 kDa protein did not bind to Sepharose 4B to which a monoclonal antibody recognising the N-terminus of fragment D was conjugated. These findings indicated that this protein was not fragment DY, but rather fibrinogen fragment X. With the retraction of the prostatic tumour by an effective therapy, the patient's AP level increased gradually. When the plasma AP level rose to 60% of normal, the fragment X was no longer detectable. These findings suggested that systemic fibrinogenolysis occurred in the patient with MPC only when AP levels were markedly decreased.
authors.affiliation: Department of Laboratory Medicine, Kumamoto University Medical School, Tokyo, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Okajima
authors.forename: I
authors.initials: I
authors.lastname: Kohno
authors.forename: J
authors.initials: J
authors.lastname: Tsuruta
authors.forename: H
authors.initials: H
authors.lastname: Okabe
authors.forename: K
authors.initials: K
authors.lastname: Takatsuki
authors.forename: B R
authors.initials: BR
authors.lastname: Binder
mesh_terms: D000368:Aged; D000911:Antibodies, Monoclonal; D005338:Fibrin Fibrinogen Degradation Products / Q000032:analysis*; D005340:Fibrinogen / Q000378:metabolism*; D006801:Humans; D015151:Immunoblotting; D007150:Immunohistochemistry; D008297:Male; D008970:Molecular Weight; D009362:Neoplasm Metastasis; D011471:Prostatic Neoplasms / Q000097:blood* / Q000473:pathology; D010959:Tissue Plasminogen Activator / Q000032:analysis*; D000979:alpha-2-Antiplasmin / Q000032:analysis*
chemical_list: D000911:Antibodies, Monoclonal; D005338:Fibrin Fibrinogen Degradation Products; D000979:alpha-2-Antiplasmin; C030568:fibrinogen fragment X; D005340:Fibrinogen; D010959:Tissue Plasminogen Activator